Advancing Science.
Backing Better Outcomes.
Our investment strategy involves partnering with the companies in which we invest. We provide the capital, expertise, and support they need to achieve their goals, with a focus on creating long-term value for our investors and contributing to the advancement of life-changing technologies and products that benefit society.
Market Environment
Insurance companies have increasingly restricted drug benefit formularies while raising rebate requirements for formulary access, often to 50% or more. At the same time, patient co-pay assistance has declined and payors continue to face the high cost of covering new therapies for life-threatening and rare diseases.
Pharmacy benefit management has also become an increasingly important source of profitability for insurers, alongside tighter restrictions on branded drug and therapeutic utilization.
Our investment strategy is designed for this more restrictive reimbursement environment, targeting differentiated therapies that we believe have the potential to achieve meaningful commercial success and generate outsized returns.
Investment Strategy
Unmet Need
We target investment opportunities in pre-clinical and early-stage clinical companies attempting to treat disease states that currently do not have an FDA approved therapy.
Cost of Care
We strongly believe reducing the cost of care coupled with clear clinical efficacy and safety will drive formulary and commercial success in a more pronounced way.
Commercial Potential
We focus on differentiated therapies with favorable reimbursement dynamics and strong potential for commercial adoption.
Portfolio Support
We uniquely offer portfolio companies expertise and experience from seasoned life sciences executives. Our experts can provide strong governance, regulatory, intellectual property, and clinical experience and insight for our portfolio companies.